cabozantinib
exelixis
['bladder', 'cabozantinib', 'biomarker']
given the use of vegf tkis for now &gt;15 yrs and failure to really identify any good biomarkers for response, sadly i don t think new biomarkers for cabozantinib in bladder cancer will be found to optimise its use. shouldn t stop the effort to investigate this #asco2022
An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family